J&J Patches Together Strong Sales Growth With Ortho EVRA, Duragesic
Executive Summary
J&J will step up promotion of Ortho EVRA in the fourth quarter, marking the end of supply constraints for the contraceptive patch
You may also be interested in...
J&J Will Maintain Rx Headcount Through 2004 Under Cost-Cutting Plan
Johnson & Johnson expects its pharmaceutical employee headcount to remain constant in 2004
J&J Will Maintain Rx Headcount Through 2004 Under Cost-Cutting Plan
Johnson & Johnson expects its pharmaceutical employee headcount to remain constant in 2004
Mylan Plans Launch Of Generic Duragesic Despite Pediatric Exclusivity
Mylan is planning to launch its generic fentanyl transdermal system by July, the date of the original patent expiration for Alza's Duragesic, despite the product's six-month pediatric exclusivity extension
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: